Keyword: Valeant

News

Valeant Slashes Stake in Allergan After Losing Bid

24.11.2014 - Valeant Pharmaceuticals International has cut its stake in US drugmaker Allergan to 0.1%, making the sale three days after Actavis trumped its offer for the Botox maker.In a...

News

Allergan Said to Have Received Bid from Actavis

04.11.2014 - Botox maker Allergan, which is fighting a hostile takeover bid by Valeant Pharmaceutical, is said to have been approached about a potential transaction by another party. The news...

News

Allergan Special Shareholder Meeting Set for December

17.09.2014 - US drugmaker Allergan, which makes the Botox anti-wrinkle treatment, said it has reached agreement with suitors Pershing Square Capital Management and Canada's Valeant...

News

Delaware Judge Fast-tracks Valeant Suit Over Allergan Meeting

29.08.2014 - A judge in the US state of Delaware has granted a request by Valeant Pharmaceuticals International and Pershing Square Capital Management, the investment vehicle of activist...

News

Ackman, Other Allergan Shareholders, Ask for Special Meeting

27.08.2014 - Led by the company's largest shareholder, Bill Ackman, investors owning 31% of Botox manufacturer Allergan have called for a special shareholder meeting. Ackman's investment...

News

Allergan Said Seeking Deal with Salix to Fend off Valeant

20.08.2014 - The share price of US drugmaker Salix Pharmaceuticals gained 16% on August 19 following a Wall Street Journal report that it and at least one other company have been approached by...

News

Allergan to Cut 13% of Jobs in Fight Against Valeant

23.07.2014 - US pharmaceutical producer Allergan, fighting a hostile bid from Quebec-based rival Valeant, has said it plans to cut 1,500 job or 13% of its workforce as part of a restructuring...

News

Shire Rejects AbbVie's £27 Billion Takeover Bid

24.06.2014 - British drugmaker Shire has rejected a £27 billion ($46 billion) takeover offer from AbbVie, the latest attempt by a US healthcare firm to tap into lower tax rates abroad via an...